| Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update JK Hicks, K Sangkuhl, JJ Swen, VL Ellingrod, DJ Müller, K Shimoda, ... Clinical pharmacology and therapeutics 102 (1), 37, 2017 | 564 | 2017 |
| Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants JK Hicks, JJ Swen, CF Thorn, K Sangkuhl, ED Kharasch, VL Ellingrod, ... Clinical Pharmacology & Therapeutics 93 (5), 402-408, 2013 | 501 | 2013 |
| Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants AM Weissman, BT Levy, AJ Hartz, S Bentler, M Donohue, VL Ellingrod, ... American Journal of Psychiatry 161 (6), 1066-1078, 2004 | 408 | 2004 |
| Antipsychotic‐induced hyperprolactinemia JR Bostwick, SK Guthrie, VL Ellingrod Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 29 (1 …, 2009 | 264 | 2009 |
| Interaction between atypical antipsychotics and the gut microbiome in a bipolar disease cohort SA Flowers, SJ Evans, KM Ward, MG McInnis, VL Ellingrod Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37 (3 …, 2017 | 206 | 2017 |
| Weight gain associated with the− 759C/T polymorphism of the 5HT2C receptor and olanzapine VL Ellingrod, PJ Perry, JC Ringold, BC Lund, K Bever‐Stille, F Fleming, ... American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 134 …, 2005 | 186 | 2005 |
| Psychosexual effects of three doses of testosterone cycling in normal men WR Yates, PJ Perry, J MacIndoe, T Holman, V Ellingrod Biological psychiatry 45 (3), 254-260, 1999 | 186 | 1999 |
| Clozapine‐induced weight gain associated with the 5HT2C receptor− 759C/T polymorphism DD Miller, VL Ellingrod, TL Holman, PF Buckley, S Arndt American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 133 …, 2005 | 179 | 2005 |
| Venlafaxine: a heterocyclic antidepressant VL Ellingrod, PJ Perry American Journal of Health-System Pharmacy 51 (24), 3033-3046, 1994 | 153 | 1994 |
| Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population MJ Bly, SF Taylor, G Dalack, R Pop‐Busui, KJ Burghardt, SJ Evans, ... Bipolar disorders 16 (3), 277-288, 2014 | 133 | 2014 |
| Serotonin 2A− 1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects JR Bishop, J Moline, VL Ellingrod, SK Schultz, AH Clayton Neuropsychopharmacology 31 (10), 2281-2288, 2006 | 133 | 2006 |
| Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer M O’Malley, AN King, M Conte, VL Ellingrod, N Ramnath Journal of thoracic oncology 9 (7), 917-926, 2014 | 132 | 2014 |
| Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C … VL Ellingrod, DD Miller, SF Taylor, J Moline, T Holman, J Kerr Schizophrenia research 98 (1-3), 47-54, 2008 | 132 | 2008 |
| Systematic review and meta-analysis of pharmacological interventions for weight gain from antipsychotics and mood stabilizers J G Fiedorowicz, D Del Miller, J R Bishop, C A Calarge, V L Ellingrod, ... Current psychiatry reviews 8 (1), 25-36, 2012 | 119 | 2012 |
| Variants of the dopamine D2 receptor and risperidone-induced hyperprolactinemia in children and adolescents CA Calarge, VL Ellingrod, L Acion, DD Miller, J Moline, MJ Tansey, ... Pharmacogenetics and genomics 19 (5), 373, 2009 | 111 | 2009 |
| C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects DI Min, VL Ellingrod Therapeutic drug monitoring 24 (3), 400-404, 2002 | 111 | 2002 |
| Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia. VL Ellingrod, JR Bishop, J Moline, YC Lin, DD Miller Psychopharmacology bulletin 40 (1), 57-62, 2007 | 100 | 2007 |
| Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics VL Ellingrod, SF Taylor, G Dalack, TB Grove, MJ Bly, RD Brook, ... Journal of clinical psychopharmacology 32 (2), 261, 2012 | 99 | 2012 |
| Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment JR Bishop, VL Ellingrod, J Moline, D Miller Schizophrenia research 77 (2-3), 253-260, 2005 | 97 | 2005 |
| CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects 1 DI Min, VL Ellingrod, S Marsh, H McLeod Therapeutic drug monitoring 26 (5), 524-528, 2004 | 94 | 2004 |
